3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation*

Background: S-adenosylmethionine-dependent methyltransferase inhibitor, DZNep, targets the degradation of histone methyltransferase EZH2 that catalyzes H3K27 trimethylation. Results: DZNep induced erythroid-related genes, which may not be directly related to EZH2 inhibition but may be partly associated with reduced protein level of hematopoietic corepressor ETO2. Conclusion: DZNep has the capacity to induce erythroid differentiation. Significance: Our data may be exploited for therapeutic applications for hematological diseases, including anemia. EZH2, a core component of polycomb repressive complex 2 (PRC2), plays a role in transcriptional repression through histone H3 Lys-27 trimethylation and is involved in various biological processes, including hematopoiesis. It is well known that 3-deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase that targets the degradation of EZH2, preferentially induces apoptosis in various hematological malignancies, suggesting that EZH2 may be a new target for epigenetic treatment. Because PRC2 participates in epigenetic silencing of a subset of GATA-1 target genes during erythroid differentiation, inhibition of EZH2 may influence erythropoiesis. To explore this possibility, we evaluated the impact of DZNep on erythropoiesis. DZNep treatment significantly induced erythroid differentiation of K562 cells, as assessed by benzidine staining and quantitative RT-PCR analysis for representative erythroid-related genes, including globins. When we evaluated the effects of DZNep in human primary erythroblasts derived from cord blood CD34-positive cells, the treatment significantly induced erythroid-related genes, as observed in K562 cells, suggesting that DZNep induces erythroid differentiation. Unexpectedly, siRNA-mediated EZH2 knockdown had no significant effect on the expression of erythroid-related genes. Transcriptional profiling of DZNep-treated K562 cells revealed marked up-regulation of SLC4A1 and EPB42, previously reported as representative targets of the transcriptional corepressor ETO2. In addition, DZNep treatment reduced the protein level of ETO2. These data suggest that erythroid differentiation by DZNep may not be directly related to EZH2 inhibition but may be partly associated with reduced protein level of hematopoietic corepressor ETO2. These data provide a better understanding of the mechanism of action of DZNep, which may be exploited for therapeutic applications for hematological diseases, including anemia.

[1]  K. Ishizawa,et al.  Role of transcriptional corepressor ETO2 in erythroid cells. , 2013, Experimental hematology.

[2]  M. Nishimura,et al.  Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. , 2012, Lung cancer.

[3]  E. Bresnick,et al.  Gene Expression Profiling Identifies HOXB4 as a Direct Downstream Target of GATA-2 in Human CD34+ Hematopoietic Cells , 2012, PloS one.

[4]  P. Atadja,et al.  Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells , 2012, Clinical Cancer Research.

[5]  E. Bresnick,et al.  GATA-1 Utilizes Ikaros and Polycomb Repressive Complex 2 To Suppress Hes1 and To Promote Erythropoiesis , 2012, Molecular and Cellular Biology.

[6]  Qiang Yu,et al.  TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep) , 2012, Clinical Cancer Research.

[7]  S. Varambally,et al.  Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. , 2012, Blood.

[8]  A. Iwama,et al.  Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. , 2011, Blood.

[9]  S. Keleş,et al.  Autophagy Driven by a Master Regulator of Hematopoiesis , 2011, Molecular and Cellular Biology.

[10]  Qiang Yu,et al.  Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells , 2011, PloS one.

[11]  A. Ciechanover,et al.  PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins. , 2011, Biochemical and biophysical research communications.

[12]  S. Orkin,et al.  Networking erythropoiesis , 2010, The Journal of experimental medicine.

[13]  Rajendran Sanalkumar,et al.  Building multifunctionality into a complex containing master regulators of hematopoiesis , 2010, Proceedings of the National Academy of Sciences.

[14]  Emery H. Bresnick,et al.  GATA Switches as Developmental Drivers* , 2010, The Journal of Biological Chemistry.

[15]  Christine Steinhoff,et al.  The genome-wide dynamics of the binding of Ldb1 complexes during erythroid differentiation. , 2010, Genes & development.

[16]  Henriette O'Geen,et al.  Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. , 2009, Molecular cell.

[17]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[18]  Peter A. Jones,et al.  DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation , 2009, Molecular Cancer Therapeutics.

[19]  Daniel Nowak,et al.  Differentiation therapy of leukemia: 3 decades of development. , 2009, Blood.

[20]  M. Szyf.  Epigenetics, DNA methylation, and chromatin modifying drugs. , 2009, Annual review of pharmacology and toxicology.

[21]  R. Hardison,et al.  SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. , 2008, Blood.

[22]  A. Hoogeveen,et al.  BMC Molecular Biology BioMed Central , 2007 .

[23]  Jonghwan Kim,et al.  Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. , 2007, Molecular cell.

[24]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[25]  G. Blobel,et al.  FOG‐1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA‐1 , 2005, The EMBO journal.

[26]  Jeroen Krijgsveld,et al.  GATA‐1 forms distinct activating and repressive complexes in erythroid cells , 2005, The EMBO journal.

[27]  Hao Wang,et al.  Global regulation of erythroid gene expression by transcription factor GATA-1. , 2004, Blood.

[28]  T. Hoang,et al.  SCL Assembles a Multifactorial Complex That Determines Glycophorin A Expression , 2004, Molecular and Cellular Biology.

[29]  Roberto Gambari,et al.  Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. , 2003, Blood.

[30]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[31]  B. Göttgens,et al.  Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors , 2002, The EMBO journal.

[32]  James R. Downing,et al.  ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain , 2001, Molecular and Cellular Biology.

[33]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[34]  James Douglas Engel,et al.  Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system , 2000, Nature Genetics.

[35]  P. Chiang.  Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. , 1998, Pharmacology & therapeutics.

[36]  T. Rabbitts,et al.  The LIM‐only protein Lmo2 is a bridging molecule assembling an erythroid, DNA‐binding complex which includes the TAL1, E47, GATA‐1 and Ldb1/NLI proteins , 1997, The EMBO journal.

[37]  S. Orkin,et al.  Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL , 1995, Nature.

[38]  Stuart H. Orkin,et al.  An early haematopoietic defect in mice lacking the transcription factor GATA-2 , 1994, Nature.

[39]  L. Degos.  Differentiation therapy of leukemia. , 1994, Leukemia & lymphoma.

[40]  J. D. Engel,et al.  Activity and tissue-specific expression of the transcription factor NF-E1 multigene family. , 1990, Genes & development.

[41]  M. Reitman,et al.  An erythrocyte-specific DNA-binding factor recognizes a regulatory sequence common to all chicken globin genes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. I. Glazer,et al.  3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. , 1986, Biochemical pharmacology.

[43]  R. I. Glazer,et al.  3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. , 1986, Biochemical and biophysical research communications.

[44]  P. Marks,et al.  The effect of erythropoietin on colonial growth of erythroid precursor cells in vitro. , 1974, Proceedings of the National Academy of Sciences of the United States of America.